Evgen Pharma is a specialist sulforaphane research and drug development company that focuses on the treatment of cancer and inflammation. They are a clinical-stage drug development company, dedicated to developing sulforaphane-based compounds that belong to a new class of pharmaceuticals. These compounds are synthesized in a proprietary, well-tolerated, and stable formulation.

Evgen Pharma's research and development efforts revolve around sulforaphane's activity in three key disease-relevant cellular pathways: inhibition of pSTAT3, up-regulation of Nrf2, and inhibition of SHP2. These pathways play a crucial role in controlling cancer metastases, oxidative stress-related diseases, and solid tumors and haematological cancers. With a comprehensive intellectual property package covering novel compositions and manufacturing methods, Evgen Pharma is at the forefront of innovative drug development.

Led by an experienced team of leaders and supported by expert advisors in the field of oncology and scientific research, Evgen Pharma is committed to advancing the treatment options for cancer and inflammation